ABM Respiratory Care Secures $20M Growth Capital Commitment

The training calendar at ABM Respiratory Care runs beside its respiratory-device catalog. Its Respiratory Care Institute offers clinicians product education, documentation and webinars, putting the work of explaining airway-clearance therapy inside the business of selling the equipment.

ABM's $20M growth capital commitment from Trinity Capital, announced October 20, 2026, supports that wider commercial effort. The medical-device company, with U.S. operations in Eagan, Minnesota, plans to expand its reach while investing in product innovation, clinical research and connected care. CEO Greg Miller and founder/CTO Vinay Joshi are building around a respiratory-care relationship that spans hospitals and homes, where distributing a machine and helping people use it are closely connected jobs.

What ABM's $20M growth commitment supports

Trinity Capital's announcement confirms the same $20M commitment and identifies commercial expansion, a stronger global presence, innovation, clinical research and connected respiratory technology as intended uses. The parties have disclosed a commitment rather than a schedule of cash received. Interest rates, maturity, draw conditions and other financing terms were not detailed in the announcements.

The distinction matters because ABM has a separate equity-financing history. In June 2025, it closed a $14.8M Series B, led by chairman Peter Soderberg, managing partner of Worthy Venture Resources, with Bluwave Capital and other investors participating. That earlier round also backed BiWaze Clear commercialization, U.S. sales, research and digital-health capabilities. Adding the two headline amounts would conceal the difference between an equity close and a capital commitment.

Trinity Capital operates a private-credit business with a dedicated Healthcare & Life Sciences practice. Rob Lake, its Senior Managing Director for that practice, represents the financing partner in the new announcement. The relationship places a specialist capital provider alongside an equipment company whose expansion involves several kinds of work at once: reaching buyers, supporting therapy, developing products and assembling clinical evidence. ABM has described where it wants to spend; the operating results will accumulate through those separate activities.

Why the BiWaze products require different conversations

BiWaze is a shared platform name, but the two principal systems address distinct airway-clearance needs. BiWaze Clear provides oscillating lung expansion therapy, combining pressure, air pulses and aerosol delivery to help mobilize secretions. Its company-described features include an integrated battery, a touchscreen and stored therapy profiles, bringing portability and repeatable settings into the product offering.

BiWaze Cough provides mechanical insufflation-exsufflation for people whose cough is ineffective. Positive air pressure is followed by negative pressure to help clear secretions, with separate pathways for inhaled and exhaled air. Understanding which mechanism a patient requires belongs to clinical care; for the business, explaining the distinction is an essential part of making the product family understandable to buyers and users.

The company describes both systems as FDA-cleared. The FDA record for BiWaze Clear independently lists a substantially-equivalent decision dated August 24, 2026. That regulatory record establishes a specific clearance milestone, while questions about comparative outcomes require their own clinical evidence. The new financing announcements do not provide revenue figures, an installed base or quantified patient-outcome improvements.

For hospitals and home-care organizations evaluating respiratory equipment, the useful commercial discussion therefore extends into training, settings, support and documentation. ABM's product pages make those needs visible through guides and educational resources. A broader distribution footprint multiplies the places where the explanation must remain clear, particularly when a familiar brand name covers therapies that work differently.

The team and support work behind respiratory-care expansion

ABM was founded in 2017. Its current leadership page identifies Vinay Joshi as founder and CTO, with prior respiratory-product experience at GE Healthcare and Hill-Rom, and Greg Miller as CEO. Miller's background includes financial and operating leadership in healthcare and industrial businesses, giving the company different kinds of experience around the same expansion plan. A 2020 company announcement also identifies Chad Boerst as a founder; that historical attribution does not establish a current operating role.

The company's locations include Eagan, Singapore and Bengaluru. That footprint gives its commercial and development work an international setting, although the new releases do not name the next markets to enter or quantify current geographic sales. Commercial expansion remains a plan with several possible routes, rather than an announced country-by-country rollout.

ABM's Respiratory Care Institute helps explain the less visible part of that plan. Training materials and webinars provide a place for care teams to learn how the therapies work, while the company describes Arc Connect as supporting engagement, therapy tracking and visibility into equipment use. The commercial opportunity is to keep the manufacturer useful after the original product demonstration, when questions become specific to the people operating the system.

For a respiratory-device business, that continuing contact can shape what the sales team needs to explain and what the development team needs to hear. ABM is directing capital toward both reach and understanding: more access to its systems, alongside research and connected-care work that can make actual use easier to follow. As BiWaze reaches additional care settings, those conversations will be carried by clinicians, representatives and the people working with the equipment between appointments.